Holen Sie sich die Stockscreener-App
0.7001
2.08%
-0.0149
Schlusskurs vom Vortag:
$0.715
Offen:
$0.71
24-Stunden-Volumen:
434.86K
Relative Volume:
0.91
Marktkapitalisierung:
$9.62M
Einnahmen:
$9.44M
Nettoeinkommen (Verlust:
$-7.58M
KGV:
-0.5863
EPS:
-1.194
Netto-Cashflow:
$-30.09M
1W Leistung:
-14.11%
1M Leistung:
-35.18%
6M Leistung:
-57.31%
1J Leistung:
-72.00%
1-Tages-Spanne:
$0.68
$0.73
1-Wochen-Bereich:
$0.6705
$0.83
52-Wochen-Spanne:
$0.6705
$3.13
Curis Inc Stock (CRIS) Company Profile
Firmenname
Curis Inc
Sektor
Branche
Telefon
617-503-6500
Adresse
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
0.7001 | 9.62M | 9.44M | -7.58M | -30.09M | -1.194 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2022-04-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-29 | Eingeleitet | Laidlaw | Buy |
| 2020-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-08-11 | Eingeleitet | FBR Capital | Outperform |
| 2015-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-21 | Bestätigt | ROTH Capital | Buy |
| 2014-05-09 | Bestätigt | Oppenheimer | Outperform |
| 2013-10-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2013-09-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2012-11-14 | Eingeleitet | Stifel Nicolaus | Hold |
| 2012-01-31 | Bestätigt | Brean Murray | Buy |
| 2012-01-31 | Bestätigt | Summer Street Research | Buy |
| 2011-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2011-10-06 | Eingeleitet | Summer Street Research | Buy |
| 2011-09-22 | Eingeleitet | MLV Capital | Buy |
| 2011-03-21 | Bestätigt | Brean Murray | Buy |
| 2010-02-26 | Bestätigt | Roth Capital | Buy |
| 2010-01-07 | Eingeleitet | Roth Capital | Buy |
Alle ansehen
Curis Inc Aktie (CRIS) Neueste Nachrichten
Curis, Inc. 2025 Annual Report: Emavusertib Development, Regulatory Pathways, and Key Business Risks - Minichart
Curis (NASDAQ: CRIS) warns on going concern amid emavusertib push - Stock Titan
CURIS (CRIS) CDO Jonathan Zung converts Series B preferred into 66,667 common shares - Stock Titan
Curis (CRIS) CMO converts Series B preferred stock to common shares - Stock Titan
CURIS INC (CRIS) CFO converts Series B preferred into 66,666 common shares - Stock Titan
Curis (CRIS) CEO converts Series B preferred stock into common shares - Stock Titan
Curis Inc (CRIS) director converts Series B preferred into 26,667 common shares - Stock Titan
[EFFECT] CURIS INC SEC Filing - Stock Titan
Curis Earnings Call: Clinical Momentum Amid Revenue Void - TipRanks
Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M - AlphaStreet
Curis (CRIS) Q4 2025 Earnings Call Transcript - AOL.com
Curis Inc stock faces renewed scrutiny amid pipeline delays and cash burn concerns - AD HOC NEWS
Curis, Inc. (NASDAQ:CRIS) Q4 2025 Earnings Call Transcript - Insider Monkey
CRIS: HC Wainwright & Co. Reiterates Buy Rating with $17.00 Pric - GuruFocus
CRIS Stock Price, Quote & Chart | CURIS INC (NASDAQ:CRIS) - ChartMill
Curis reports Q4 results, secures up to $80.8M financing By Investing.com - Investing.com India
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ... By GuruFocus - Investing.com Canada
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit and Strategic Focus - GuruFocus
Curis Q4 2025 Earnings Call Transcript - MarketBeat
Curis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Curis targets full enrollment in PCNSL registrational study within 12–18 months while advancing CLL proof-of-concept - MSN
Earnings call transcript: Curis Inc. Q4 2025 sees turnaround with net income - Investing.com India
Curis Inc’s NHL Prioritization, PCNSL Timeline Shifts, and CLL Data Delays Clash in 2025 Q4 Earnings Call - Bitget
Curis Reports Progress on Lymphoma Study & Expands CLL Research with EmavusertibNews and Statistics - IndexBox
Curis (CRIS) Q4 2025 Financial Results Conference Call Transcript - Bitget
Earnings call transcript: Curis Inc. Q4 2025 sees turnaround with net income By Investing.com - Investing.com South Africa
Curis: Fourth Quarter Earnings Overview - Bitget
Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Curis (CRIS) Q4 2025 Earnings Call Transcript - The Motley Fool
Curis Provides Fourth Quarter 2025 Business Update - Bitget
Curis (CRIS) Reports Lower Than Expected Q4 Revenue - GuruFocus
Curis Q4 & Full-Year 2025 Financial Results: $19.4M Net Income, $1.1M RevenueNews and Statistics - IndexBox
Curis: Overview of Fourth Quarter Financial Results - Bitget
Curis reports Q4 results, secures up to $80.8M financing - Investing.com
Curis Inc Q4 revenue misses estimates - TradingView
Curis: Q4 Earnings Snapshot - marketscreener.com
Curis (CRIS) swings to Q4 profit but warns of funding shortfall - Stock Titan
Curis’s Emavusertib Trial Pause: What AML and MDS Investors Need to Know - TipRanks
Curis Shareholders Approve Major Equity and Charter Changes - The Globe and Mail
Curis (NASDAQ: CRIS) CDO acquires Series B preferred and warrants - Stock Titan
Curis (CRIS) CMO acquires Series B preferred stock and warrant package - Stock Titan
Curis (CRIS) CFO granted preferred stock and multi-series warrant package - Stock Titan
Curis (CRIS) CEO receives Series B preferred stock and large warrant grants - Stock Titan
Curis (CRIS) director receives Series B preferred and multi-series warrant grants - Stock Titan
Curis, Inc. 8-K SEC Filing Details: Company Information, Address, and Regulatory Compliance (March 17, 2026) - Minichart
Curis (NASDAQ: CRIS) ups share authorization and clears expansive 2026 incentive plan - Stock Titan
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026 - BioSpace
CRIS Earnings History & Surprises | EPS & Revenue Results | CURIS INC (NASDAQ:CRIS) - ChartMill
Finanzdaten der Curis Inc-Aktie (CRIS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):